Roche Holding Ltd. (ADR) - RHHBY - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: May 19, 2013

Roche Holding Ltd. (ADR) - SIC # 2834

Ticker	Exchange	SIC #	Website	Latest Ticker
RHHBY	Over the counter	2834	http://www.roche.com	65.65 +0.94
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Roche Holding Ltd. (ADR) Positive Data on Roche Candidate - May 22nd, 2013 3:15 pm Bristol-Myers jumps after Citi ups rating on cancer potential - May 22nd, 2013 8:33 am On The Fly: Analyst Upgrade Summary - May 22nd, 2013 8:00 am 1 Big Pharma Phase 3 Failure - May 21st, 2013 7:07 pm Roche, Sigma-Aldrich teamed for Life bid, Reuters says - May 21st, 2013 6:03 pm Positive Data on Novartis' Afinitor - May 21st, 2013 3:30 pm Roche, Reloaded - May 21st, 2013 1:05 pm After A Big Rally, Pfizer Might Need Some Rest - May 21st, 2013 9:45 am Will ASCO Unlock Big Value in This Cancer Drug Class? - May 18th, 2013 12:30 pm Bristol-Myers, Merck And Roche: R&D Finds Golden Pill, So Buy - May 17th, 2013 5:25 am Good News for Roche's Tarceva - May 16th, 2013 4:00 pm Pipeline Progress at Gilead - May 16th, 2013 11:30 am Melanoma Treatment Harnesses Immune System to Combat Cancer Cells - May 15th, 2013 7:01 pm Cancer Meeting Highlights the Good and Bad of the Immune System - May 15th, 2013 5:10 pm ASCO '13 Preview: New 'Anti-PD-1' Therapies Shrink Tumors - May 15th, 2013 4:00 pm ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up - May 15th, 2013 4:00 pm Genentech’s Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Common Forms of Blood Cancer - May 15th, 2013 4:00 pm Nektar Posts Wider Loss, Maintains View - May 15th, 2013 9:45 am Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO - May 14th, 2013 11:00 pm FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung Cancer - May 14th, 2013 5:14 pm View All Current Headlines >>